Unicycive Therapeutics (UNCY) Accumulated Depreciation (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Accumulated Depreciation came in at $58000.0 in Q1 2026, up 23.4% YoY from $47000.0 in Q1 2025, and down 19.44% on a QoQ basis from $72000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Accumulated Depreciation (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Accumulated Depreciation data on file, last reported at $58000.0 in Q1 2026.
- Quarterly Accumulated Depreciation rose 23.4% year-over-year to $58000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58000.0 (up 23.4% YoY) and the FY2025 annual result came in at $72000.0, up 84.62% from the prior year.
- Accumulated Depreciation eased to $58000.0 in Q1 2026, from $72000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $72000.0 in Q4 2025 to a low of $4000.0 in Q2 2022.
- A 5-year average of $29625.0 and a median of $22000.0 in 2024 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation surged 600.0% — and 2026, when it rose 23.4%.
- Tracing UNCY's Accumulated Depreciation over 5 years: stood at $7000.0 in 2022, then soared by 128.57% to $16000.0 in 2023, then jumped by 143.75% to $39000.0 in 2024, then soared by 84.62% to $72000.0 in 2025, then retreated by 19.44% to $58000.0 in 2026.
- The last three Accumulated Depreciation figures came in at $58000.0 (Q1 2026), $72000.0 (Q4 2025), and $63000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65,000.00 |
| Mar 31, 2026 | 58,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Sep 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 25,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Dec 31, 2021 | 1,000.00 |